

<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Atty. Docket No.:</b> 180.00120101	<b>Serial No.:</b> 10/591,199
	<b>Applicant(s):</b> Zhao Yi Wang	<b>Confirmation No.:</b> 4302
	<b>Application Filing Date:</b> June 13, 2007	<b>Group:</b> 1647
	<b>Information Disclosure Statement filed:</b> January 18, 2010	

**U.S. PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		5,312,752	05/17/94	Wotiz et al.			

**U.S. PATENT APPLICATIONS BY SERIAL NUMBER**

Examiner Initial	Copy Enclosed	Document Number	Filing Date	Name	Class	Subclass
		None				

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		None						

**OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)**

Examiner Initial	Copy Enclosed	Document Description
	X	Acs et al., "Immunohistochemical Expression of Erythropoietin and Erythropoietin Receptor in Breast Carcinoma," <i>Cancer</i> , 2002 September 1; 95(5):969-981.
	X	Fukazawa et al., "Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated Extracellular-regulated Kinase (ERK) Pathway," <i>Molecular Cancer Therapeutics</i> , 2002 March; 1:303-309.
	X	Renzi, et al., "Erythropoietin down regulates SHP1 and induces a sustained activation of ERK1/ERK2 in primary cortical neurons," <i>Blood</i> , 2001 November 16; 98; 1 page - abstract only.

<b>EXAMINER</b> /Shulamith Shafer/	<b>Date Considered</b> 01/25/2010
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	